41491-53-6

Usage

Uses

Used in Pharmaceutical Industry:
2-(3-Bromophenyl)-5-methyl-1,3,4-oxadiazole is used as a potential active pharmaceutical ingredient for its potential anticancer properties. 2-(3-Bromophenyl)-5-methyl-1,3,4-oxadiazole is being studied for its ability to target and inhibit the growth of cancer cells, making it a promising candidate for the development of new cancer therapies.
Used in Antibacterial Applications:
In the field of antimicrobial research, 2-(3-Bromophenyl)-5-methyl-1,3,4-oxadiazole is utilized as a potential antibacterial agent. Its structure may contribute to its effectiveness against certain types of bacteria, offering a new avenue for the development of antibiotics to combat bacterial infections.
Used in Medicinal Chemistry Research:
2-(3-Bromophenyl)-5-methyl-1,3,4-oxadiazole serves as a valuable compound in medicinal chemistry research. Scientists are investigating its biological activities to understand its mechanisms of action and to potentially modify its structure to enhance its therapeutic effects or to reduce potential side effects.
Used in Drug Development:
In the drug development process, 2-(3-Bromophenyl)-5-methyl-1,3,4-oxadiazole is employed as a lead compound. Its unique structure and potential biological activities make it a candidate for further optimization and development into effective drugs for various medical conditions, including cancer and bacterial infections.

InChI:InChI=1/C9H7BrN2O/c1-6-11-12-9(13-6)7-3-2-4-8(10)5-7/h2-5H,1H3

Upstream product

• 585-76-2 m-bromobenzoic acid 
• 489455-69-8 tert-butyl 2-(3-bromobenzoyl)hydrazinecarboxylate 
• 39115-96-3 3-bromo-benzoic acid hydrazide 
• 78-39-7 Triethyl orthoacetate 

Relevant academic research and scientific papers

BIARYL PYRAZOLES AS NRF2 REGULATORS

The present invention relates to biaryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

Efficient synthesis of 1,3,4-oxadiazoles promoted by NH4Cl

An efficient and inexpensive approach to the synthesis of 2-substituted and 2,5-disubstituted 1,3,4-oxadiazoles from arylhydrazides and orthoesters is reported using catalytic NH4Cl. The conditions are mild, and thus, compatible with a variety of functional groups. The optimized reaction is performed using 30 mol % of NH4Cl in 100% EtOH and is generally complete within 1 h for non-aromatic orthoesters and 2-10 h for aromatic orthoesters. The reaction permits both electron-releasing and electron-withdrawing groups on the arylhydrazide substrate. Most products are formed in high yields and require only minimal purification. Compared with earlier reports, the current reactions proceed in shorter time and require less of the orthoester.

Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR

The biphenyl amides are a novel series of p38 MAP kinase inhibitors. Structure-activity relationships of the series against p38α are discussed with reference to the X-ray crystal structure of an example. The series was optimised rapidly to a compound showing oral activity in an in vivo disease model.

2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1-isoxazolyl, R1-oxadiazolyl, R1-dihydrofuranyl, R1-pyrazolyl, R1-imidazolyl, R1-pyrazinyl or R1-pyrimidinyl; R1 is 1, 2 or 3 substituents selected from H, alkyl, alkoxy and halo; Z is optionally substituted-aryl, or optionally substituted-heteroaryl; are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations with other agents.